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Abstract: Reduced activity of CNS serotonin is reported in unipolar depression and serotonin is the major target of recent 
antidepressant drugs. However, an acute depletion of serotonin in healthy individuals does not induce depressive symp-
toms suggesting that depression does not correlate with the serotonin system only. Neuronal plasticity (structural adapta-
tion of neurons to functional requirements) includes synthesis of microtubular proteins such as tyrosinated isoform of -
tubulin and presence of serotonin as regulator of synaptogenesis. In depression neuronal plasticity is modified.  
Here, in rats submitted to a behavioural test widely used to predict the efficacy of antidepressant drugs (forced swimming 
test: FST) a significant decrease of both cerebral tyrosinated -tubulin expression and serotonin levels is monitored. 
Moreover, treatment with para-chlorophenylalanine (PCPA, compound that specifically depletes brain serotonin) but not 
alpha-methyl para tyrosine (-MPT, compound that blocks synthesis of catechols: chemicals also implicated in depres-
sion) significantly reduced tyrosinated -tubulin. Thus, a direct relationship between serotonin and tyrosinated -tubulin 
appears to be present both in “physiological” and in “pathological” states. In addition, data obtained in animals submitted 
to FST and/or treated with the selective serotonin reuptake inhibitor (SSRI) fluoxetine further support the interrelationship 
between central serotonin and cytoskeleton. These data propose that direct relationship between serotonin and tyrosinated 
-tubulin could be considered within the mechanism(s) involved in the pathogenesis of depression. 
Keywords: Rat brain, monoamines, serotonin, microtubules, tyrosinated -tubulin. 
1. INTRODUCTION 
  The cytoskeleton is the structural component of neurones 
and three polymers, i.e. microtubules, intermediate filaments 
and microfilaments are their components [1].  
  Microtubules derive from the polymerisation of tubulin 
proteins (heterodimers consisting of - and - sub-units), 
they are abundant in neurones and exhibit high heterogeneity 
of components. Furthermore, microtubules are highly dy-
namic polymers as they exchange rapidly the polymerised 
tubulin dimers with soluble sub-unit pools. This feature is 
involved in fundamental cellular functions such as cell divi-
sion, motility and transport, maintenance of cell shape and 
signal transduction [2]. 
 The  -tubulin sub-unit of the microtubule is expressed in 
mammalian species in various isoforms related to different 
primary sequences and several post-translational modifica-
tions. One of these modifications is the cyclic tyrosination / 
detyrosination of the C-terminus, cycle that has been shown 
to occur in many cell types and to be related to the microtu-
bule dynamic [3]. Stable microtubules are detyrosinated [4], 
whilst the highly dynamic microtubules show to be highly 
tyrosinated [3].  
  High levels of tyrosinated -tubulin (Tyr-tub) are cur-
rently used as a marker of dynamic forms of microtubules [3,  
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5, 6]. Its expression is increased in physiological events such 
as the development of the central nervous system [7, 8] as 
well as pathological events such as experimental epilepto-
genesis, characterised by neuronal plasticity [9].  
  Neuronal plasticity is the capability of neurones to mod-
ify their structural organisation in order to adapt to new func-
tional requirements. It plays a crucial role within brain de-
velopment and in many physiological processes of mature 
brain such as learning and memory [10]. Neuronal plasticity 
requires the presence of serotonin (5-HT) as regulator of 
synaptogenesis [11] and cytoskeletal states necessary for 
synaptic remodelling i.e. dynamic form of microtubules [12]. 
Indeed, a more dynamic microtubule (major presence of 
soluble form versus insoluble form) is essential for rapid 
intracellular events resulting in elongation or shortening of 
cell processes, which are essential morphogenetic events 
during neurogenesis [1].  
  Recently, basic and clinical studies have provided direct 
evidence of neuronal plasticity failure in response to stress 
and depression that leads to neuronal atrophy, cell death and 
neurogenesis decrease in the hippocampus [13-16].  
  Several neurotransmitters have been implicated in the 
pathogenesis of depression. Reduced activity of monoamines 
such as 5-HT and noradrenaline (NA) systems has been re-
ported in sub-groups of patients with major depression [17] 
and antidepressant drugs act mostly via increased amount of 
such neurotransmitters in the synaptic space. 
  To date the 5-HT system is one of the major targets of 
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hibitors (SSRIs) are highly effective, producing milder side 
effects than tricyclic antidepressant drugs [17- 21]. 
  However, depletion of 5-HT or NA in healthy subjects 
does not induce clinically significant depressive symptoma-
tology. Thus, abnormalities in other neurobiological systems 
may play a role in depressive symptomatology [17]. For in-
stance, various studies have proposed that the increased cen-
tral 5-HT levels following a long-term antidepressant treat-
ment activate several post-receptor signalling pathway and in 
particular that of Protein Kinase A (PKA) in microtubules, 
resulting in the inhibition of microtubule assembly [12, 22-
24].  
  The consequent major dynamic instability of the micro-
tubules may favour the cytoskeletal changes necessary for 
long-term (plastic) modifications in neurotransmission [25]. 
Taken together with the neuronal plasticity failure observed 
in stress and depression, these findings support the cy-
toskeleton as one of the systems involved in depression.  
  In the present study, that follows preliminary work pre-
sented to the 15th ECNP Congress [26], experiments have 
been performed in order to monitor a putative interrelation-
ship between cytoskeleton and cerebral monoamines. In par-
ticular, the influence of pharmacological depletion of 
catechols or serotonin (5-HT) upon Tyr-tub levels has been 
analysed. Naive rats were treated either with -methyl-para-
tyrosine (MPT) that blocks synthesis of catechols [27, 28] 
or with para-chlorophenylalanine (PCPA) a tryptophan hy-
droxylase inhibitor that conspicuously decreases central 5-
HT content without altering 5-HT terminal density [29, 30].  
  Finally the FST: an animal model widely used to predict 
the efficacy of antidepressant drugs as it is stated by the first 
author proposing such behavioural model [31] and then 
adopted by the researchers of the field, was applied either 
alone or in presence of treatment with fluoxetine. Therefore 
this model considered as “predictor” of the efficacy of anti-
depressant drugs such as the SSRIs was used in order to ana-
lyse the two systems studied i.e. 5-HT and cytoskeleton, 
within either a condition that could mimic a “depressive 
state” and following treatment with an “antidepressant drug“. 
2. METHODS 
2.1. Animals 
  Adult male Sprague Dawley rats (250-300g) were used. 
All housing and experimental procedures were carried out in 
accordance with the Italian law (Legislative Decree no.116, 
27 January 1992), which acknowledges the European Direc-
tive 86/609/EEC, and were fully compliant with GlaxoS-
mithKline policy on the care and use of laboratory animal 
and codes of practice. Furthermore, all efforts were made to 
minimize the number of animals used and their suffering. 
2.2. Treatments  
  Adult male Sprague Dawley rats (250-300g) were treated 
with: 
1)  PCPA (500mg/kg i.p. n=4) or  
2) with  MPT (250mg/kg i.p. n=4) or  
3)  vehicle (NaCl 0.9% 2ml/kg i.p., n=4, control group). 
  24 hours later rats were anesthetised with chloral hy-
drate (400mg/kg i.p.), then were sacrificed, the brains 
were removed and homogenised in lysis buffer. 
  Subsequently, concomitant electrochemical analysis 
of both DA and 5-HT levels (using differential pulse 
voltammetry, see below) and Tyr-tub expression 
(western blot) were performed in each brain ho-
mogenate.  
4)  In other animals, acute treatment with fluoxetine 
(SSRI 20mg/kg i.p., n=4) or vehicle (NaCl 0.9% 
2ml/kg i.p., n=4, control group) was performed. Two 
hours later rats were anesthetised with chloral hydrate 
(400mg/kg i.p.), then were sacrificed, the brains were 
removed and homogenised in lysis buffer. 
Subsequent analysis of both 5-HT levels (voltammetry, see 
below) and Tyr-tub expression (western blot) were per-
formed.  
2.3. Western Blot Procedure 
  Tyr-Tub expression was evaluated in brain homogenate 
by densitometric quantification of related band previously 
obtained via western blot. 
  In particular, brains were homogenised in lysis buffer 
[5mM Tris-HCl, 2mM EGTA, 0.1mM phenylmethylsulfonyl 
fluoride (PMSF), 0.1mM pepstatin A, 1 mM leupeptin, 1mM 
aprotinin, pH 8.0]. Protein concentrations were determined 
via  colorimetric assay (Bradford protein assay; Bio-Rad 
Hercules, CA, USA), setting the spectrophotometer to 595 
nm. Samples (10μg of total proteins) were diluted in sample 
buffer [62.5mM Tris-HCl pH 6.8, 20% glycerol, 2% sodium 
dodecyl sulfate (SDS), 5% -mercaptoethanol, 0.5% bromo-
phenol blue (BPB)]. Protein samples were heated for 3 min 
at 99°C and proteins were separated on SDS - 12% poly-
acrylamide gel electrophoresis, at 40 mA for 1hr and then 
transferred onto nitrocellulose membranes using a dry trans-
fer unit at 50mA overnight. A molecular size marker (200-
6.5kD range; Bio-Rad) and pure tubulin (ICN Costa Mesa, 
CA, USA) were used in order to exactly locate tubulin 
(55kD) on the basis of its position on the gel. The mem-
branes were blocked for 2 hours with 5% skimmed powder 
milk in Tris-buffered saline (TBS) and incubated 1hr at 4°C 
with monoclonal antibodies clone TUB-1A2 (Sigma) spe-
cific to Tyr-Tub at 1:1000 dilution in 0.1% skimmed powder 
milk in TBS. The membranes were then incubated with a 
1:5000 IgG anti-mouse alkaline phosphatase antibody 
(Promega Madison, WI, USA) for 30 min and the reaction 
developed using a stabilized substrate for alkaline phospha-
tase (Western Blue; Promega). The immunoreactivity of the 
Tyr-Tub bands obtained was quantified by densitometry 
(Molecular Analyst Software; Bio-Rad). 
2.4. Voltammetry and Carbon Fibre Micro Electrodes 
(Micro-Biosensors) 
  Within the different voltammetric methodologies avail-
able, Differential Pulse Voltammetry (DPV, that is a linear 
voltammetric technique with superimposed constant pulses 
(△V: 50mV; t: 50ms) has been selected since this technique 
exhibits both a high selectivity and sensitivity (for a review 
see Stamford et al. [32]). DPV was applied by means of the 
polarograph  AUTOLAB (EcoChemie, The Netherlands) Further Electrochemical and Behavioural Evidence  The Open Neurology Journal, 2010, Volume 4    7 
linked to IBM computer with voltammetric analysis program 
(General Purpose Electrochemical System Software package 
(GPES). The three-electrode potentiostat system needed to 
apply voltammetry was prepared as described previously 
[32, 33]. Briefly, the reference electrode was silver/silver 
chloride (Ag/AgCl) and the auxiliary (counter) electrode was 
a silver wire, both approximately 100m diameter. The 
working electrode was the 30m diameter mCFE prepared 
and treated as previously described in order to increase the 
sensitivity, selectivity and reliability of the micro-sensor 
(34). Briefly, a 70 Hz triangular wave form was applied in 
three stages, 0 to +3 Volts for 8 sec.; 0 to +2.6 V and 0 to 
+1.5 V for 10s each. Then, two successive continuous poten-
tials were applied to the mCFE: +1.45V and -0.9V, 5 s each. 
This electrochemical treatment was carried out with the aux-
iliary, reference and working electrodes immersed in 0.1M 
phosphate-buffered saline (PBS) at pH 7.4. It affects the ac-
tive part of the working electrode i.e. the tip of the protrud-
ing carbon fibre from the end of the glass pipette (0.5-1.0 
mm length; 30m diameter). Then the tip was coated with 
Nafion as described in details by Crespi et al. [34]. Briefly: 
the tip of the mCFE was immersed four times (approxi-
mately 2 sec each time) into a Nafion drop (10l of 5% solu-
tion, Solution Technology, Mendehall, PA) placed into a 
loop (about 3 mm diameter) formed at one end of a platinum 
wire of 100m in diameter. The other end of the wire was 
connected to the reference and auxiliary outputs of the po-
larograph and a d.c. potential of + 3.5 V was applied. The 
Nafion-coated mCFE was then dried at 60°C for 20 sec and 
used immediately for the experiments. This electrochemical 
treatment was shown to increase sensitivity, selectivity and 
reliability of the micro-sensor to quantification of dopamine 
and noradrenaline [catecholamines, both having similar oxi-
dation potential value] and serotonin [34-36]. 
  The following measuring DPV parameters were chosen: 
initial potential (Ei) -100 mV, final potential (Ef) +350mV to 
monitor catecholamines and 5-HT in the same scan voltam-
mogram. Scan step was 10mV•s-1 scan duration, 30s, filter 
0.1 Hz. Other polarographic parameters employed were cho-
sen according to Crespi et al. [34]. 
2.5. Forced Swimming Test 
  Other groups of naive rats were submitted to FST as de-
scribed by Porsolt et al. [31], except that the water was 
deeper [37]. Briefly, each animal was placed in a cylinder 
(40cm height; 18cm diameter) containing 30cm water main-
tained at 26-28°C. The modification of FST (30 cm water 
deep) avoids false immobility due to the capability of adult 
rats to rest on the tail when touching the bottom of the cylin-
der in a lower volume i.e. 15 cm as described by Porsolt et 
al. [31].  
  In a recent paper, the influence of “cold” water upon rat 
behaviour and in particular immobility within FST was dis-
cussed [38]. In our hand rats submitted to FST with water at 
the temperature of 26-28°C were showing significant differ-
ent behaviour immobility in function of different treatments 
(see Results and Discussion).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Tyr-Tub (55kDa) immunoreactivity in brain homogenate: western blot bands (left) quantified by densitometric analysis and con-
comitant DPV measurements (right) after acute treatment with PCPA 500mg/kg i.p. (TOP) or with MPT 250mg/kg (BOTTOM). Results 
are expressed as percent of control (vehicle treated rats); n=4 each histogram, mean ± S.D. *p<0.05, Dunnett’s test.  
Note the significant decrease, (F1,12= 7,5264 p<0.05) of Tyr-Tub following PCPA versus MPT treatment. 
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  After a pre-test session (day 1) of 15 min each rat was 
dried (under warm air current) and twenty-four hours later 
exposed again to FST during 5 min.  
  Both saline and fluoxetine sub-chronic treatment was 
performed 23h, 5h and 1h prior to the FST as previously 
described [37, 39]. The behaviour was monitored during the 
first 5 min of the pre-test and the following day for all the 
five 5 min of the FST.  
  A time-sampling method was used as described previ-
ously [37] in order to score several behaviours during a sin-
gle viewing. This method has been selected as it has shown 
to be reliable and valid for detecting the effect of different 
antidepressant drugs. In particular, immobility and swim-
ming were monitored in 5-sec period. Briefly, immobility 
was scored when the animal was making the minimum 
movements necessary to keep its head above water and stay 
afloat. Swimming was scored when the animal actively 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). TOP LEFT: schematic representation of the carbon fibre microelectrode used in the present experiments.  
TOP RIGHT: differential pulse voltammogram obtained in vitro with Nafion mCFE: dotted line shows signals obtained in phosphate buffer 
solution (PBS, pH 7.4), solid line shows Peak 1 at approximately 69mV and Peak 2 at approximately 230mV corresponding to the oxidation 
of catecholamines [dopamine or noradrenaline] and 5-HT, respectively (50nM in PBS). 
h: height of the peak, measured in nanoAmperes (nA: Intensity of current). This perpendicular line also determined the exact potential value 
expressed in Volts (V) of each signal on the abscissa.  
MIDDLE: differential pulse voltammogram obtained in vitro with Nafion mCFE within 200l sample of the brain homogenate of a naïve (A) 
rat or a rat submitted to FST (B) (LEFT) and in six rats each group (RIGHT). 
BOTTOM: In the same 200l sample brain homogenate the Tyr-Tub (55 kDa) western blot immunoreactivity was performed (left) and quan-
tified by densitometric analysis (right). 
Results are expressed as percent of control (naive rats); n=6 each histogram, mean ± S.D. **p<0.01, Dunnett’s test.  
    
 
                             
 
 
 
 
Peak 1      Peak 2 
 
2nA 
 
A 
 
 
B 
* 
protruding 
active tip of 
the mCFE: 
500µm 
O        .1       .2       .3 V   
Western Blot 
 
                   
        
kDa 
 91 
     Tyr-Tub 
       45 Further Electrochemical and Behavioural Evidence  The Open Neurology Journal, 2010, Volume 4    9 
swam around the tank, making movements greater than that 
necessary to stay afloat.  
  Three groups of animals (n=4 each group) were submit-
ted to FST: untreated rats (naive, n=4) or rats pre-treated 
with vehicle (NaCl 0.9%) or fluoxetine as described above. 
  Immediately after FST, each rat was sacrificed, the brain 
was removed and homogenised in lysis buffer so that ex vivo 
parallel experiments could be performed to monitor 5-HT 
levels and Tyr-Tub expression.  Briefly, 5-HT levels were 
selectively measured within 200l sample of brain ho-
mogenate using DPV associated with carbon fibre micro-
electrodes (mFE) coated with Nafion [34]. In the same brain 
homogenate assessed with DPV-mCFE the Tyr-Tub (55 
kDa) western blot immunoreactivity was performed and 
quantified by densitometric analysis. 
2.6. Drugs 
 PCPA,  MPT, chloral hydrate, (Sigma St. Louis, MO, 
USA), fluoxetine (Tocris); Nafion (Aldrich).  
2.7. Statistical Analysis 
  The data obtained from all the experiments were ana-
lyzed using analysis of variance (ANOVA) and the post-hoc 
test were conducted using Dunnett’s test.  
3. RESULTS 
3.1. Pharmacological Treatments 
i)  PCPA treatment resulted in a significant decrease of 
Tyr-Tub expression in the whole brain (approxi-
mately 75% of vehicle treated rats (NaCl 0.9% 600 l 
i.p., control rats) (Fig. 1 TOP).  
ii)  In contrast, no significant changes were monitored in 
MPT treated rats (Fig. 1 BOTTOM).  
  Concomitant DPV measurements in the same ho-
mogenate resulted in a large decrease to approxi-
mately 45% or 12% of control values of both the 
catecholaminergic (Peak 1) and the 5-HT (Peak 2) re-
lated signals, respectively (Fig. 1 right, see also Fig. 2 
for technicality).  
iii)  Acute fluoxetine (20 mg/kg i.p.) resulted in a signifi-
cant increase of both 5-HT levels and Tyr-tub expres-
sion in whole brain up to approximately 217±40% 
and 203±24%, respectively, of control rats treated 
with NaCl 0.9% (vehicle) 600 l i.p. (Fig. 3).  
3.2. Forced Swimming Test 
i)  FST significantly increased immobility counts from 
19.8±1.5 (untreated rats) or from 16.8±1.0 (vehicle 
treated rats) recorded in the pre-test day, up to 
31.4±3.9 or to 31.0±2.1 gathered in day 1, respec-
tively (mean ±SEM) (see Table 1).  
  In fluoxetine treated rats submitted to FST, immobil-
ity latency appeared to be increased (approximately 
45s) while immobility counts were significantly de-
creased (22.8±2.7, mean ±SEM) when compared to 
untreated rats (31.4±3.9) or vehicle treated rats 
(31.0±2.1). Furthermore, fluoxetine treated rats 
showed higher swimming behaviour and active be-
haviour counts when compared to untreated or vehi-
cle treated rats. In contrast, climbing behaviour 
counts were similar in all animals tested (Table 1). 
ii)  Immediately after FST, rats were sacrificed. The 
brains were immediately removed and homogenised. 
Successive concomitant electrochemical [voltammet-
ric] and western blot analyses were performed in the 
whole brain homogenate of rats submitted to FST and 
showed that: 
a)  In vehicle treated rats 5-HT levels and Tyr-tub ex-
pression were both significantly decreased by FST to 
approximately 69±11% and 87±4% of corresponding 
levels monitored in naive control rats (Fig. 4). These 
data are in accord with the results gathered from the 
previous groups of animals submitted to FST and then 
tested for Tyr-tub expression and 5-HT levels as de-
scribed in Fig. (2) middle and bottom. 
b)  In fluoxetine treated rats submitted to FST, 5-HT lev-
els and Tyr-tub expression reached 120±16% and 
103±5% of corresponding levels monitored in naive 
control rats, respectively. On the other hand, when 
compared to data gathered from vehicle treated rats 
submitted to FST and considered 100%, these differ-
ences were approximately 150% and 116%, respec-
tively (Fig. 4). 
c)  in naive rats submitted to FST only, changes in 5-HT 
levels and Tyr-tub expression were very close to 
those monitored in vehicle + FST treated rats (Fig. 4).  
DISCUSSION 
 Earlier  in vitro studies have indicated that long-term an-
tidepressant SSRI treatment inhibits microtubule assembly 
via  PKA pathway activation [12]. This suggests that in-
creased 5-HT levels (due to chronic SSRI treatment) precede 
the inhibition of microtubule assembly and therefore the in-
crease of its dynamic instability.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Effect of acute treatment with fluoxetine alone (20 mg/kg 
i.p. n=4) or vehicle alone (NaCl 0.9% 2ml/kg i.p., n=4, control 
group) upon voltammetric 5-HT levels or Tyr-tub expression in rat 
whole brain. Both parameters were significantly increased: F1,8= 
8.202 p<0.05) and F1,7= 7.727 p<0.05, respectively. 
Data are expressed as % of control (vehicle), mean± S.D. *p<0.05, 
Dunnett’s test.  
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Table 1. 
 
BEHAVIOUR   Untreated Rats 
 pre-test  FST 
ANOVA 
immobility latency (sec)  114 ± 18  67 ± 11   F1,9=5.07 p=0.0543 
immobility (counts)  19.8 ± 1.5  31.4 ± 3.9*  F1,9= 7.47 p=0.0257 
swimming (counts)  21.8 ± 2.5  11.4 ± 3.6*  F1,9=5.38 p=0.0489 
climbing (counts)  16.6 ± 3.3  17.2 ± 3.7  F1,9=0.01 p=0.9082 
diving (counts)  1.8 ± 0.8  0  F1,9=5.06 p=0.0546 
active (counts)  40.2 ± 1.5  28.6 ± 3.9*  F1,9=7.47 p=0.0257 
  Vehicle Rats  
 pre-test  FST 
ANOVA 
immobility latency (sec)  110 ± 17  65 ± 8*  F1,9=5.95 p=0.0405 
immobility (counts)  16.8 ± 1  31 ± 2.1**  F1,9= 34.52 p=0.0004 
swimming (counts)  19.4 ± 3.7  14.8 ± 2  F1,9=1.13 p=0.3173 
climbing (counts)  21 ± 2.9   14.2 ± 1.6  F1,9=4.15 p=0.076 
diving (counts)  2 ± 1.2  0  F1,9=2.5 p=0.1525 
active (counts)  42.4 ± 1.6  29 ± 2.1**  F1,9=24.39 p=0.0011 
 FLUOXETINE  Rats 
 pre-test  FST  ANOVA 
immobility latency (sec)  124 ± 19  112 ± 19  F1,9=0,60 p=0.4579 
immobility (counts)  17.6 ± 1.9  22.8 ± 2.7  F1,9= 2.90 p=0.1266 
swimming (counts)  19.2 ± 5  20.6 ± 2.7  F1,9=0.06 p=0.7987 
climbing (counts)  22.6 ± 3.2  15 ± 3.4  F1,9=2.45 p=0.156 
diving (counts)  1.8 ± 1.2  0  F1,9=2.25 p=0.172 
active (counts)  43.6 ± 3.3  35.6 ± 2.8   F1,9=3.80 p=0.0868 
  POST-HOC= *p<0.05 **p<0.01 pre-test vs FST (Dunnett's Test) 
 
  Our curiosity was then to analyse the possibility that 
these two systems could be interrelated and that changes in 
central serotonin could drive cytoskeleton modifications. 
This hypothesis, firstly indicated in a presentation to the 15th 
ECNP Congress Barcelona - Spain, 5 - 9 October, 2002 [26] 
has been further tested via various analytical approaches: 
1. Treatment with PCPA or -MPT 
  These are compounds that selectively deplete central 5-
HT or catechols, respectively [40, 41]. The present data indi-
cate that only depletion of central 5-HT by PCPA resulted in 
significant changes in Tyr-tub levels. PCPA could have an 
independent action upon the cytoskeleton. On the other hand 
these data may support a putative interaction between central 
5-HT system and cytoskeleton dynamics while indicating 
absence of such interaction for what concerns the catechola-
minergic system.  
2. Acute Treatment with Fluoxetine (SSRI) 
  This was performed in order to influence the central sero-
tonergic system and to verify putative subsequences on both 
5-HT levels and Tyr-tub expression. This resulted in a sig-
nificant increase of both 5-HT levels and Tyr-tub expression 
in whole brain up to approximately 217% and 203% of sa-
line treated rats, respectively. 
  Up to date the 5-HT system is still one the major target of 
antidepressant SSRIs [17-21] thus the variation of 5-HT lev-
els was to be expected. 
  Additionally, it is known that fluoxetine is a lipophilic 
chemical that can be located in subcellular fragments pre-
pared from brain tissue of fluoxetine-treated rats [42]. There-
fore, fluoxetine may enter the cell and interact with mono-
amine oxidase (MAO), enzyme present in both neurons and 
glia and that metabolises the classical monoamine neuro-
transmitters [43]. Consequently, the therapeutic actions of 
fluoxetine may [also] involve an inhibition of such enzyme 
and in particular the form MAO-B, which would result in a 
greater amount of 5-HT available for release as indeed al-
ready reported [44]. Furthermore, in vitro and in vivo study 
have shown that doses of 20 mg/kg produced a more-than-
20% decrease in MAO A activity and a 10–15% suppression 
of MAO B activity in the rat brain [45, 46].  
  Clinical studies have also shown that fluoxetine and other 
SSRI antidepressants, used at low dosage are beneficial in 
psychiatric disorders because they increase the availability or Further Electrochemical and Behavioural Evidence  The Open Neurology Journal, 2010, Volume 4    11 
potency of neuroactive GABAergic steroids [for reviews see 
47-49]. It appears that their ability to increase brain steroid 
biosynthesis is occurring at doses [i.e. 5mg/kg in rats] devoid 
of significant action on brain 5-HT reuptake mechanisms 
[50, 51]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). TOP: 5-HT levels monitored by means of ex vivo DPV and  
BOTTOM: Tyr-Tub (55 kDa) western blot immunoreactivity re-
corded in brain homogenates of naive (unstressed) rats or rats sub-
mitted to FST, FST + vehicle treatment or FST + fluoxetine treat-
ment, respectively. 
Results are expressed as percent of control (naive rats); n=5 each 
histogram,  
mean ± S.D.  
Stats for 5-HT data:  
  ANOVA treatment effect: F3,20= 5.52504 p=0.0078 
  *p<0.05 Unstressed versus FST or FST+ vehicle (Fisher's LSD 
Test) 
  ##p<0.01 FST versus FST+fluoxetine (Fisher's LSD Test) 
  $$p<0.05 FST+ vehicle versus FST+fluoxetine (Fisher's LSD 
Test) 
Stats for Tyr-Tub data:  
  ANOVA treatment effect F3,54= 4.87733 p=0.0047 
  *p<0.05 **p<0.01 Unstressed versus FST or FST+vehicle 
(Fisher's LSD Test) 
  ##p<0.01 FST versus FST+fluoxetine (Fisher's LSD Test) 
  $p<0.05 FST+vehicle versus FST+fluoxetine (Fisher's LSD 
Test)  
  *p<0.05 Unstressed vs FST or FST+saline (Fisher's LSD Test) 
  ##p<0.01 FST vs FST+fluoxetine (Fisher's LSD Test) 
  $$p<0.05 FST+saline vs FST+fluoxetine (Fisher's LSD Test) 
  Therefore they are proposed as new class of pharmacol-
ogical tools for the management of anxiety, related mood 
disorders, dysphoria, and impulsive aggression so called 
“selective brain steroidogenic stimulants” (SBSSs). The mo-
lecular mechanisms subserving the fluoxetine induced facili-
tation on neurosteroidogenesis remain to be investigated and 
defined in terms of structural chemical related specificity in 
activating brain steroidogenesis, which is a novel and in-
triguing branch of psychopharmacology. 
  In our work, the dose of fluoxetine used is superior to the 
5mg/kg and already proven to act on the changing of mono-
amine concentrations at the synapses via the selective inhibi-
tion of 5-HT reuptake. Nevertheless, these two components 
of fluoxetine central mechanism of action have to be consid-
ered when regarding its influence on cytoskeletal dynamics. 
It is definitely known that some neurosteroids have a direct 
action on cytoskeletal protein such as as the microtubule 
associated protein 2 (MAP2) that has an important role in 
neuronal morphogenesis stimulating for instance the exten-
sion of neurites [52].  
  Indeed, results suggest that MAP2 expression may be 
necessary for both neurite extension and cessation of cell 
division as the specific suppression of MAP2 synthesis pre-
vents the neuronal differentiation of embryonic carcinoma 
cells exposed to retinoic acid, as shown by the absence of 
neurites [53]. 
  On the other hand, the proposed modification of Tyr-tub 
is an original observation. It could be due to an SSRI direct 
action on the cytoskeleton and/or it could be successive to 
changes on central serotonin activity, opening to the hy-
pothesis of an interrelationship between these two systems.  
3. FST 
  Such postulation was also challenged in animals submit-
ted to FST following vehicle or fluoxetine treatment as de-
scribed by Porsolt et al. [31]. FST is an animal model of de-
pression widely used to predict the efficacy of antidepressant 
drugs [31]. Successively ex vivo analysis of brain 5-HT lev-
els and Tyr-tub expression were performed. These two latter 
measurements were also carried out in control naive rats. 
  The pre-test session of the FST (15 min swimming, day 
1) induces a state of behavioural despair that is thought to 
increase the duration of immobility during the 5 min swim-
ming test session of day 2 (FST) [39]. Accordingly, here the 
rats submitted to FST did show a significant (p<0.05 Dun-
nett’s test) increase of immobility up to approximately 158% 
of the values gathered in day 1 (pre-test day). In addition, 
during the FST, the fluoxetine treated rats displayed signifi-
cantly lower immobility and higher swimming counts when 
compared to saline treated rats. Climbing counts were simi-
lar in both type of treatment (Table 1). In the successive par-
allel  ex vivo electrochemical and western blot studies in 
whole brain it was observed that:  
i)  In saline treated rats 5-HT levels and Tyr-tub expres-
sion were both decreased to approximately 69% and 
88% of corresponding levels monitored in naive con-
trol rats, respectively. 
ii)  In fluoxetine treated rats 5-HT levels and Tyr-tub 
expression were both increased up to approximately 
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naive control rats, respectively. On the other hand, 
when compared to data gathered from vehicle treated 
rats, these differences were approximately 150% and 
120%, respectively. 
  In addition, naive rats were submitted to FST in order to 
analyse the putative influence of systemic injection of vehi-
cle (NaCl 0.9%, 600l i.p.) upon the parameter measured. 
The data gathered within the naive rats were very similar to 
those observed in vehicle treated rats (see Table 2). Thus, 
injection of vehicle did not alter significantly the effect of 
FST upon 5-HT levels and Tyr-tub expression. Therefore, 
this data indicate that the reduction of 5HT levels and Tyr-
tub expression following FST is not altered significantly by 
the manipulation of the animal when submitted to i.p. treat-
ment, thus supporting both these reductions as directly re-
lated to the FST and independent from the putative stressful 
manipulation of the animal due to the systemic injection.  
  These original parallel electrochemical and western blot 
results further support such combined methodology as useful 
concomitant analytical approach indicating that in rats sub-
mitted to FST a reduced neuronal plasticity can be detected 
together with coupled decreased activity of central seroton-
ergic system. They are in agreement for instance and there-
fore corroborate with separate experiments showing i) the 
neuronal plasticity failure [13-15] and ii) the reduced central 
5-HT levels in condition of depression [17].  
  All these data support a strict relationship between 5-HT 
and cytoskeleton as the two systems are modified in a paral-
lel way in all the different types of treatments. Again, the 
pharmacological or behavioural induced changes of seroton-
ergic levels were expected as already reported in the litera-
ture, while the original observation that FST modifies Tyr-
tub expression may lead to the hypothesis of a primary influ-
ence of the central 5-HT system upon the cytoskeleton con-
dition. It has been shown that different acute stressful condi-
tions [i.e. 5-min forced swim in cold water] result in hyper-
phosphorylation of microtubule-associated proteins such as 
TAU [54] and that neuronal TAU hyperphosphorylation de-
creases microtubule dynamics resulting in neuronal plasticity 
impairment [55]. 
  On the other hand, fluoxetine was reported to have the 
ability to reverse stress-induced changes [56, 57] and that 
fluoxetine increases the phosphorylation of MAP-2 [58] that 
is amongst neuronal microtubule-associated proteins (MAPs) 
an abundant group of cytoskeletal components. This activity 
promotes microtubule dynamics [59] resulting in more Tyr-
Tub expression [5, 26]. In the literature this type of studies is 
generally performed in the hippocampus, the evidence in our 
work that such effect of fluoxetine is detected in the whole 
brain may indicate a general activity over the CNS of such 
compound.  
  In conclusion, the present work supports the preliminary 
hypothesis about a direct serotonin and neuronal plasticity 
relationship [26] as it proposes that changes in central 5-HT 
levels obtained either within a behavioural test resulting in 
stress and/or depression states (FST) or via selective phar-
macological treatments (i.e. PCPA, fluoxetine treatment) 
have direct influence upon the microtubular network result-
ing in modified activity of the neuronal plasticity.  
  In particular, the original hypothesis that the decreased 5-
HT levels observed in depression [17] may be selectively 
correlated to a reduced dynamic instability of the microtubu-
lar network could be formulated.  
  Finally, the direct relationship observed between 5-HT 
and the microtubular network can be proposed as a mecha-
nism involved in the control of mood which may be an inno-
vative target for alternative therapeutic approaches to treat 
depression. 
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